Examkin

Soru

Zorluk: ZorPharmacologic Interventions

An internal medicine physician is providing follow-up care for a 61-year-old patient with nonischemic cardiomyopathy in the outpatient clinic. The patient's most recent echocardiogram demonstrates a left ventricular ejection fraction of 28%. The patient's current medication regimen consists of carvedilol, spironolactone, dapagliflozin, and sacubitril-valsartan.

On physical examination, blood pressure is 118/74 mmHg, pulse is 68/min, and respiratory rate is 14/min. Jugular venous pressure is estimated at 6 cm H2O. Lungs are clear to auscultation bilaterally, and there is no lower extremity edema. Pertinent laboratory studies reveal a serum sodium of 139 mEq/L, potassium of 4.6 mEq/L, and creatinine of 1.1 mg/dL.

During the visit, the patient expresses concern regarding a recent loss of prescription drug coverage, stating that the sacubitril-valsartan has become financially prohibitive. After discussing alternatives, the physician and patient agree to discontinue the sacubitril-valsartan and initiate oral lisinopril to maintain optimal guideline-directed medical therapy. The patient confirms taking the final dose of sacubitril-valsartan this morning at 8:00 AM.

Based on pharmacologic safety guidelines, which of the following is the most appropriate instruction for initiating lisinopril in this patient?

  1. Instruct the patient to take the first dose of lisinopril tomorrow evening at 8:00 PMCevap
  2. B
    Start lisinopril this evening at 8:00 PM to prevent a gap in neurohormonal blockade
  3. C
    Prescribe lisinopril to begin tomorrow morning at 8:00 AM and advise monitoring for a dry cough
  4. D
    Cross-taper the sacubitril-valsartan with lisinopril over the next five days to ensure hemodynamic stability
  5. E
    Withhold all renin-angiotensin-aldosterone system inhibitors for seven days to ensure complete neprilysin clearance

Cevap

The most appropriate instruction is to advise the patient to take the first dose of lisinopril tomorrow evening at 8:00 PM, exactly 36 hours after the final dose of the ARNI.
The correct action is to mandate a 36-hour washout period after the last dose of an angiotensin receptor-neprilysin inhibitor (ARNI) before initiating an angiotensin-converting enzyme (ACE) inhibitor. Because both neprilysin and ACE are primarily responsible for the degradation of bradykinin, concurrent inhibition or an insufficient washout period leads to excessive bradykinin accumulation and a high risk of life-threatening angioedema. The FDA strictly mandates a 36-hour washout period when switching between these two classes. Since the patient took the last ARNI dose at 8:00 AM today, the earliest safe time to administer lisinopril is exactly 36 hours later, which is 8:00 PM tomorrow.

Adım Adım Çözüm

1
Identify the pharmacologic classes involved in the medication transition
The patient is switching from sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor or ARNI) to lisinopril (an angiotensin-converting enzyme or ACE inhibitor).
Different medication transitions in heart failure management have specific safety protocols based on their mechanisms of action and pharmacokinetic profiles.
2
Recall the safety guidelines regarding overlapping neprilysin and ACE inhibition
Concurrent use of ARNIs and ACE inhibitors is absolutely contraindicated due to a synergistic increase in bradykinin, which can cause life-threatening angioedema.
Both neprilysin and ACE are major enzymes responsible for the degradation of bradykinin. Blocking both pathways simultaneously severely impairs bradykinin clearance.
3
Determine the required medication washout period
A strict 36-hour washout period is required when transitioning from an ARNI to an ACE inhibitor, or from an ACE inhibitor to an ARNI.
This 36-hour interval allows sufficient time for neprilysin clearance and normal bradykinin metabolism to resume before introducing an ACE inhibitor.
4
Calculate the correct initiation time based on the patient's last dose
The last ARNI dose was taken at 8:00 AM today. Adding 36 hours results in an earliest safe initiation time of 8:00 PM tomorrow.
To provide accurate prescribing instructions that maximize safety while avoiding an unnecessarily prolonged gap in neurohormonal blockade.

Anahtar Kavram

When transitioning a patient between an angiotensin receptor-neprilysin inhibitor (ARNI) and an ACE inhibitor, a strict 36-hour washout period is required to prevent life-threatening angioedema caused by excessive bradykinin accumulation.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru